Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
Novartis pays $150M for Arvinas' prostate tumor protein degrader
The deal, which is worth up to $1.01 billion in milestones, will give Novartis global rights to a degrader of wild-type and mutant androgen receptor.
Nick Paul Taylor
Apr 11, 2024 8:04am
Prostate cancer ADC breaks FibroGen's clinical losing streak
Apr 3, 2024 10:55am
AstraZeneca melds with Fusion in $2B radiopharma buyout
Mar 19, 2024 5:52am
Janux's shares jump 130% following T-cell engager data drop
Feb 27, 2024 10:35am
Pfizer funnels $15M into 3-year cancer care disparity initiative
Feb 5, 2024 10:00am
Next-gen PSA test maker Cleveland Dx rocks to $75M fundraising
Jan 29, 2024 11:07am